IMA today
$3.40-$0.05 (-1.45%)close Nov 13, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minConsolidating
Daily trend turns up above $6.21
Key levels
Resistance$4.45
Resistance$3.88
Latest news & SEC filings
EarningsImageneBio Posts Q3 2026 Results
EarningsImageneBio posts wider quarterly loss than analysts expected
SEC FilingImageneBio, Inc. filed a report on a major company event (Form 8-K)
All IMA news →About ImageneBio
ImageneBio is an early-stage drug developer focused on therapies for immune-related and inflammatory conditions. Its main candidate, IMG-007, is an antibody that targets the OX40 receptor without depleting T cells, and it is being tested first in atopic dermatitis, with possible future work in alopecia areata and asthma. The company runs trials in North America and Canada, aiming its products at people with moderate-to-severe inflammatory skin disorders.
Based on the company's 10-K filed Mar 10, 2026.
Nasdaq · Healthcare
ImageneBio, Inc. (IMA)
What Is the Price Target for IMA?
SEPT Low Target
$28.00
SEPT Mid Target
$28.00
SEPT High Target
$28.00
Analyst Consensus
$28.00
Is IMA a Buy or Sell Right Now?
Thesis
- •Revenue growing -77.1% YoY with DECLINING trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for IMA.
Start Free Trial →Is IMA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$26.40
12
Moat Score
NONE
4/9
Piotroski Score
-1.5
Altman Z-Score
What Is Smart Money Doing with IMA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
MEDIUM
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →IMA Growth Story
Revenue YoY
-77.1%
3yr Revenue CAGR
-62.9%
EPS Growth YoY
56.38%
FCF Growth YoY
N/A%
Revenue Trend
DECLINING
Dark Pool Trades for IMA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for IMA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:19:30 | $3.58 | 1,000 | $$4K | SELL |
| 18:18:29 | $3.65 | 1,003 | $$4K | BUY |
| 16:03:37 | $3.74 | 1,000 | $$4K | BUY |
| 15:33:28 | $3.88 | 2,869 | $$11K | SELL |
| 15:28:23 | $4.07 | 1,000 | $$4K | BUY |
5 dark pool trades shown · $$26K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for ImageneBio, Inc. (IMA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (0 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →IMA — frequently asked questions
What is IMA stock price today?
ImageneBio, Inc. (IMA) is at $3.40, down 1.45% (-$0.05) at the Nov 13, 2026 close.
Why is IMA stock moving today?
Latest IMA news — Nov 10, 2026: ImageneBio Posts Q3 2026 Results · Nov 9, 2026: ImageneBio posts wider quarterly loss than analysts expected
What is the IMA price target?
The average analyst price target for IMA is $28.00, ranging from $28 to $28, based on 1 analysts. Latest: HC Wainwright & Co. initiates on Aug 21, 2026.
What do analysts rate IMA?
Analyst ratings for IMA: 1 Buy, 0 Hold, 0 Sell — consensus Buy.
Did IMA beat earnings?
IMA last reported on Aug 5, 2026: EPS -$0.63 vs -$0.98 expected — a beat of 35.5%.
Does IMA pay a dividend?
IMA does not currently pay a dividend.
What are IMA support and resistance levels?
Resistance: $3.88, $4.45, $5.10.
What are insiders doing with IMA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on IMA?
Nov 10, 2026: ImageneBio Posts Q3 2026 Results · Nov 9, 2026: ImageneBio posts wider quarterly loss than analysts expected · Nov 9, 2026: ImageneBio, Inc. filed a report on a major company event (Form 8-K)